SkyQuest Technology Group recently introduced Microbiome Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Microbiome Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Global Microbiome Market size was valued at USD 911.0 million in 2023 and is poised to grow from USD 1072.25 million in 2024 to USD 3949.18 million by 2032, growing at a CAGR of 17.7% during the forecast period (2025-2032).
Microbiome is a collection of microorganisms that live on and within our bodies. The United States National Institutes of Health (NIH) started the Human Microbiome Project to increase understanding of the microbial flora involved in human health and disease. The market is expanding as a result of factors such as an increase in the number of strategic alliances for microbiome therapies for R&D, product development, the anticipated introduction of innovative medications, and portfolio enhancement. For example, Hudson Institute and BiomeBank announced a four-year agreement in January 2022 to develop and discover microbial treatments. Furthermore, the increasing prevalence of target diseases is driving up demand for microbiome therapies.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/microbiome-market
The 2025 global Microbiome Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Microbiome Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on global industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Microbiome Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Microbiome Market is segmented by Product, Application and region.
Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others.
Based on Application, the market is segmented into Therapeutics and Diagnostics.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Microbiome Market – Regional Analysis:
North America is expected to account for the lion’s share of the global human microbiome market. The region’s domination is due to the rising prevalence of lifestyle problems and advances in next-generation sequencing. For example, Illumina Inc., a major player in the United States, claims that the introduction of next-generation sequencing enables various high-profile joint projects, like the Human Microbiome Project and MetaHIT. Using Next Generation Sequencing as a basic tool, these projects have published a wide range of data on the human microbiome.
Europe is likely to increase its market share during the forecast period as a result of extensive research and development of novel human microbiome applications. According to NCBI, new microbiome programmes such as ONCOBIOME, MICROB-predict, and GEMMA are focused on oncology, mapping of human microbiota, and autistic spectrum disorders, respectively, and are expected to boost market expansion in this region in March 2020.
Top Market Players in Microbiome Market are:
Seres Therapeutics (USA)
Ferring Pharmaceuticals (Switzerland)
BiomeBank (Australia)
Seed Health (USA)
International Flavors & Fragrances Inc. (USA)
Pendulum Therapeutics (USA)
BioHM Health Inc. (USA)
Actial Farmaceutica SRL (Italy)
Optibiotix Health plc (UK)
Resbiotic (USA)
Infinant Health Inc. (USA)
Biogaia AB (Sweden)
Exegi Pharma LLC (USA)
Vedanta Biosciences Inc. (USA)
Enterome (France)
Yakult (Japan)
DuPont (USA)
Metabiomics Corporation (USA)
ViThera Pharmaceuticals (USA)
Second Genome (USA)
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/microbiome-market
Microbiome Market Recent Developments:
In September 2022, Seres Therapeutics Inc completed the FDA BLA submission procedure for SER-109 to prevent recurrent C. difficile infection (rCDI). It is a completely novel therapy approach that has the potential to improve the existing standard of care for rCDI.
In September 2022, The FDA’s Vaccines and Related Biological Products Advisory Committee approved Ferring Pharmaceuticals’ RBX2660 investigational microbiota-based live biotherapeutic research for its potential to decrease the recurrence of C. difficile infection (CDI) after antibiotic therapy.
Take Action Now: Secure Your Microbiome Market Today – https://www.skyquestt.com/buy-now/microbiome-market
Forward-Looking Insights
The Microbiome Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
